Biographical Sketch  

Provide the following information for the key personnel in the order listed for Form Page 2.

Follow the sample format for each person. DO NOT EXCEED FOUR PAGES.




Nammalwar Sriranganathan





EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)



(if applicable)



University of Agricultural Sciences, Bangalore,



Veterinary Medicine and Surgery

University of Agricultural Sciences, Bangalore,




Oregon State University, Corvallis, OR



Molecular Biology

American Veterinary Medical Association



Veterinary medicine and Surgery

Am. Coll. of Vet. Microbiologists.



Veterinary Microbiology



A.  Positions and Honors


2002-present Professor

1990-2002       Associate Professor,

1984-1990       Assistant Professor,   Department of Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg. Va 24061-0442           

1979-1984       Assistant Professor, College of Veterinary Medicine, Washington State University, Pullman, Washington.(1983-84) Assistant Professor, University of Wyoming, Laramie, Wyoming.

1976-1978       Postdoctoral Teaching  & Research Associate, USDA/NIH.WSU. WA

1974-1975       Clinical Intern, Veterinary Clinic. Centralia, Washington.

1970-1974       Research Assistant, Oregon State University, Corvallis. Oregon.

1969-1970       Instructor, Mysore College of Veterinary Medicine, Bangalore.

1968-1969       Veterinary Surgeon, Civil Veterinary Hospital, Bangalore.


National Merit Loan Scholarship. 1966-68

Predoctoral Research Assistantship. 1970-74

Research Associate NIH A&ID Grant 1976-77          

Research Associate USDA. 1977-78

Who's Who in Southern United States


License:         Licensed to practice veterinary medicine in the States of Washington and Oregon, 1976



B.     Selected peer-reviewed publications (in chronological order)

Winter, A.J., G.G. Schurig, S.M. Boyle, N. Sriranganathan, J.S. Bevins, F.M. Enright, P.H. Elzer, and J.D. Kopek. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from B. melitensis and B. suis biovar 4. Amer. J. Vet. Res. 57:677-683, 1996.


Jablonski*,P.E., L.M. Jablonski, O.Pintado, N. Sriranganathan, and C.J. Hovde. Identification of Pasteurella multocida tryptophan synthase b-subunit by antisera against strain P1059. Microbiol. 142:115-121. 1996.


Zhi-Jun Yin*,N. Sriranganathan, T. Vaught, S.K. Arastu, Ansar Ahmed, S. A Dye-Based Lymphocyte Proliferation Assay that Permits Multiple Immunological Analyses: mRNA, Cytogenetic, Apoptosis, and Immuno-phenotyping Studies. Journal of Immunological Methods. 210:25-39. 1997.


Vemulapalli, R., Duncan, J, McQuiston, J.R., Schurig, G.G., Toth, Sriranganathan, N. and Boyle, S.M. Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune response to YajC in mice vaccinated with B. abortus RB51. Infection and Immunity 66:5684-5691. 1998.


Wise, D.J., N. Sriranganathan, S.M. Boyle, G.G. Schurig.  Evaluation of the intracellular growth of various Brucella species in J774A.1and PU5-1.8 macrophage like cell lines as an in-vivo mode of assessing attenuation in-vivo. In: Networking in Brucellosis Research II, United Nations University Press. J. Frank, ed, pp: 93-110, 1998.


Vemulapalli R,  JR McQuiston, G.G. Schurig, N Sririanganathan, SM Halling and SM Boyle. Identification of an IS711 element interrupting the wboA gene of Brucella abortus vaccine strain RB51 and a PCR assay to distinguish strain RB51 from other Brucella species and strains.  Clin Diagn Lab Immunol. 6:760-4, 1999.


McQuiston JR, R. Vemulapappi, TJ Inzana, G.G. Schurig, N Sririnaganathan, D Fritzinger, TL Hadfield, RA Warren, N Snellings, D Hoover, SM Halling and SM Boyle. Genetic characterization of a Tn5-disrupted glycosyltransferase gene homolog in Brucella abortus and its effect on lipopolysaccharide composition and virulence. Infect Immun. 67: 3830-5, 1999.


Vemulapalli R, Cravero S, Calvert CL, Toth TE, Sriranganathan N, Boyle SM, Rossetti OL, Schurig GG. Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus. Clin Diagn Lab Immunol Jan;7(1):114-118.2000.


Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle SM, Schurig GG. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of brucella abortus strain RB51. Infect. Immun. 68(6):3286-9. 2000


Vemulapalli, R., He, Y., Boyle, S.M., Sriranganathan, N., Schurig, G.G. Brucella abortus RB51 as a vector for heterologous protein expression and induction of specific Th-1 type immune responses in mice. Infection and Immunity68(6): 3290-3296. . 2000.


Vemulapalli, R., He, Y., Buccolo, L. S., Boyle, S.M., Sriranganathan, N., Schurig, G.G. Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in its rough phenotype and attenuation. Infection and Immunity. 68(7): 3927-3932. 2000.


Baloglu, S., T.E. Toth, G.G. Schurig, N. Sriranganathan, and S.M. Boyle. Humoral immune response of BALB/c mice to a Vaccinia virus recombinant expressing Brucella abortus GroEL does not correlate with protection against a B. abortus challenge. Vet. Microbiol. 76:193-199. 2000.


Walsh, C.P., R. Vemulapalli, N. Sriranganathan, A. M. Zajac, M. Jenkinsb, D. S. Lindsay* Molecular comparison of the dense granule proteins, GRA6 and GRA7 of Neospora hughesi from Neospora caninum. International Journal of Parasitology. 31:253-258. 2001.


Fernandez-Prada CM, Nikolich M, Vemulapalli R, Sriranganathan N, Boyle SM, Schurig GG, Hadfield TL, Hoover DL. Deletion of wboA Enhances Activation of the Lectin Pathway of Complement in Brucella abortus and Brucella melitensis. Infect Immun. 69:4407-4416. 2001.


Karpuzoflu, S.E., Y. Zhi-Jun, N. Sriranganathan, and Ansar Ahmed, S. Effects of Long-Term Estrogen Treatment on IFN-gamma, IL-2 and IL-4 Gene Expression and Protein Synthesis in Spleen and Thymus of Normal C57BL/6 Mice. Cytokine. 14:208-217. 2001.


Altekruse SA, Elvinger F, DebRoy C, Pierson, FW, Eiffert JD, Sriranganathan, N. Pathogenic and fecal Escherichia coli strains from turkeys in a commercial operation. Avian Dis,46:562-569. 2002.


Altekruse SA, Elvinger F, Lee KY, Tollefson LK, Pierson FW, Eifert JD, Sriranganathan, N. Antimicrobial susceptibilities of Escherichia coli strains from a turkey operation. JAVMA, 221:411-416. 2002.


Schurig, G.G., N. Sriranganathan, and M. J. Corbel. Brucellosis Vaccines: Past, Present and Future. Journal of Veterinary Microbiology, 90:479-496. 2002.


Vemulapalli, R., Y. He, N. Sriranganathan, S. M. Boyle, and G. G. Schurig.  Brucella abortus RB51: Enhancing Vaccine Efficacy and Developing Multivalent Vaccines. Veterinary Microbiology,90: 521-532. 2002.


Whichard, J.M., N. Sriranganathan, and F.W. Pierson. "Suppression of Salmonella growth by wild-type (WT) and large-plaque (LP) variants of bacteriophage Felix O1 in liquid culture and on chicken frankfurters."   Journal of Food Protection 66(2):220-5. 2003.


Contreras-Rodriguez, Araceli., Bernardo Ramirez-Zavala, Andrea Contreras, G. G. Schurig, N. Sriranganathan, and Ahide Lopez-Merino. Purification and characterization of an immunogenic  aminopeptidase of Brucella melitensis. Infection and Immunity 71(9):5238-5244.2003.


Baloglua, Simge , Stephen M. Boyle, Ramesh Vemulapallia, Nammalwar Sriranganathan, Gerhardt G. Schurig and Thomas E. Toth. Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein. Submitted to Veterinary Mirobiology. Under review. 2004


Seleem, M.N., R. Vemulapalli, S.M. Boyle, G.G. Schurig and N. Sriranganathan. Improved expression vector for Brucella species. BioTechniques. 37:740-744.November, 2004.


Vemulapalli, R., A. Contreras, N. Sanakkayala, N. Sriranganathan, S. M. Boyle, and G. G. Schurig. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Vet Microbiol. 102:237-245. 2004.




















C. Other Research Support         Nammalwar Sriranganathan


USDA-NRI 2002-02181: Brucella abortus RB51-based live recombinant vaccine against Neosporosis. 

Role: PI: N. Sriranganathan, 20%. S.M. Boyle, D. Lindsey, G.G. Schurig. Direct cost $72,000/year for two years. August 2002 to August 2005 with a year of no-cost extension.

Several Brucella –Neospora bivalent vaccines have been generated and tested in mouse lethal model. Two candidate vaccines that induced protection in this model will be tested in pregnant mouse model for their ability to prevent abortions due to Brucellosis and Neosporosis.  

These vaccine candidates are specifically developed for veterinary use and there is no scientific overlap between the USDA and current NIH-RO1 application.


NIH –PO1: Program Project: Respiratory Immunity Against Agents of Bioterrorism. PD: S. Mizel of Wake Forest University. Sept, 2004-August 2009.

Role: Director: Animal Challenge Core. N. Sriranganathan 20% effort. Yersinia pestis mouse challenge model development and testing of vaccines developed by Wake Forest University investigators.


US-ARMY (DOD): Development of a multi biothreat agent vaccine for humans:

Role: PI’s G.G. Schurig, S.M. Boyle and N. Sriranganathan. 20%. $110,000/year for three years, July 2001 to August 2005 with no cost extension.

B. abortus RB51 a current vaccine as a platform for the expression of heterologous protective antigens from anthrax in order to develop multivalent vaccine.  Several candidate vaccines have been tested in mouse Brucella challenge model with minimum protection against an anthrax lethal challenge, but excellent protection against Brucella melitensis challenge.


NIH- R21AI057875-01: Gene Expression In Brucella-infected Macrophages:

Role:PI’s. Y. He, R. Lathigra, S.M. Boyle, N. Sriranganathan, G. G. Schurig. 10% effort,  $200,000/year for two years Feb 2004, to Feb 2006.

Study of host response to infection by rough (a virulent) and smooth (virulent) strains of Brucella in mouse macrophage cell line using Affymetrix microarray chip.  There is minimum of overlap, as this research will be focused only on macrophage cell line responses to Brucella infection.


NIH- R21AI60702-01: (High – PI): Brucella, Aging and the Role of IL-17 in Host Defense. August 2004-July 2006  Role: Co -Investigator N. Sriranganathan (10% effort), S.M. Boyle and G. Schurig. $200,000 Direct per year for two years. NS is primarily responsible for all of the animal studies at Virginia Tech.






NIH-RO1: PI’s: R. Vemulapalli, CO-I’s : Nammalwar Sriranganathan (5%) and Gerhardt Schurig.

Role: Subcontract: Animal Challenge studies $56,000/year Direct for the last three years of a 4 yr RO1. “Non-replicative vaccine for human brucellosis.”  Development and testing in mice of candidate vaccines against Brucellosis in human beings. There are no age related immune response is being evaluated in this proposal.


NIH-R21: PI: Aloka Bandara, S.M. Boyle, Nammalwar Sriranganathan (5%), and Gerhardt Schurig. $150,000/year direct cost for two years. “Characterization of carboxyl-terminal protease of Brucella.” Characterization of carboxyl-terminal protease, it’s role in host-pathogen interaction and virulence, there is no overlap with the RO1 (PI: Vemulapalli) proposal being considered for funding.

 [JG1]For any page on which you wish to edit a Header or Footer, select “Unprotect Document” under the Tools menu, double-click in the Header/Footer, and enter text. Re-protect forms: Select “Protect Document for FORMS” under the Tools menu.